Orexo AB

Orexo AB

ORXOF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.87M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Orexo ABOrexo AB-0.1--211%--
$1.23

Current Fair Value

1409.1% upside

Undervalued by 1409.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.87 Million
Enterprise Value$-143,133,685.00
Earnings per Share$-3.74
Beta0.89
Outstanding Shares35,126,410

Return

Return on Equity-211.39%ROE
Return on Assets-99.47%
Return on Invested Capital-180.65%

Valuation & Multiples

P/E Ratio-0.08P/E Ratio
PEG-0.04PEG
Price to Sales-Price to Sales
Price to Book Ratio0.02Price to Book Ratio
Enterprise Value to Revenue-9.14
Enterprise Value to EBIT0.32
Enterprise Value to Net Income0
Total Debt to Enterprise-0.06
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 22, 2026
EPS
-$0.21
Est. -$0.21
Revenue
$447,750
Est. $447,750

Next Earnings Call

Expected Date
February 4, 2027
EPS Estimate
-$0.12
Consensus analyst estimate
Revenue Estimate
$591,600
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Orexo AB

65 employees
CEO: Nikolaj Sorensen

Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United St...